Compare Docusign Inc (DOCU) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Docusign Inc vs Heron Therapeutics Inc — how do they compare? Docusign Inc trades at $71 (market cap $12.88B), while Heron Therapeutics Inc trades at $0.37 (market cap $74.04M). The key difference: Docusign Inc is far larger — about 174× Heron Therapeutics Inc's market cap, and Docusign Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Docusign Inc for 71 Days and Heron Therapeutics Inc for 35 Days on average.
| DOCU | HRTX | |
|---|---|---|
Market Cap | $12.88B | $74.04M |
Volume | 2,591,969 | 3,668,095 |
Sector | Technology | Health |
52-Week High | $73.14 | $1.49 |
52-Week Low | $41.75 | $0.27 |
Typical Hold Time | 71 Days | 35 Days |
Enterprise Value | $12.28B | $180.78M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOCU trades at $71.43, up 4.71% with a bullish technical signal and strong earnings momentum, having beaten EPS estimates for three consecutive quarters. The company shows robust revenue growth reaching $2.98B in 2025 with improving profit margins, though valuation ratios remain elevated. Recent news highlights AI integration in contract processing and leadership recognition in workflow software.
Outlook remains positive with projected revenue growth to $3.4B in 2026, supported by AI adoption and operating leverage. Risks include insider selling, competitive pressures, and high valuation multiples. Analyst consensus is cautious with 64% hold ratings, but technical strength and fundamental improvements suggest potential for continued upside if execution persists.
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Docusign Inc
DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
